Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory

被引:38
作者
Vo, Teresa T. [1 ]
Bell, Gillian C. [2 ]
Obeng, Aniwaa Owusu [3 ,4 ]
Hicks, J. Kevin [5 ]
Dunnenberger, Henry M. [6 ]
机构
[1] Univ S Florida, Coll Pharm, Dept Pharmacotherapeut & Clin Res, Tampa, FL USA
[2] Mission Hlth, Personalized Med Program, Asheville, NC USA
[3] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA
[4] Mt Sinai Hosp, Dept Pharm, New York, NY 10029 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, DeBartolo Family Personalized Med Inst, Dept Individualized Canc Management, Div Populat,Sci, Tampa, FL USA
[6] NorthShore Univ HealthSyst, Ctr Mol Med, Evanston, IL USA
来源
PHARMACOTHERAPY | 2017年 / 37卷 / 09期
关键词
pharmacogenomics; pharmacogenetics; clinical implementation; precision medicine; PREEMPTIVE PHARMACOGENOMICS; CLINICAL IMPLEMENTATION; DECISION-SUPPORT; HEALTH SYSTEM; IMPACT; MODEL; STANDARDIZATION; INFORMATION; CHALLENGES; PHENOTYPE;
D O I
10.1002/phar.1985
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
One of the initial steps for implementing pharmacogenomics into routine patient care is selecting an appropriate clinical laboratory to perform the testing. With the rapid advances in genotyping technologies, many clinical laboratories are now performing pharmacogenomic testing. Selection of a reference laboratory depends on whether a particular genotype assay is already performed by an internal health care organization laboratory or only available externally. Other factors for consideration are coverage of genomic variants important for the patient population, technical support, and cost. In some instances, the decision to select a particular reference laboratory may be the responsibility of the clinician who is recommending genomic interrogation. Only limited guidance is available that describes the laboratory characteristics to consider when selecting a reference laboratory. We provide practical considerations for selecting a clinical laboratory for pharmacogenomic testing broadly categorized into four domains: pharmacogene and variant selection; logistics; reporting of results; and test costs along with reimbursement.
引用
收藏
页码:1014 / 1022
页数:9
相关论文
共 40 条
[1]   Saliva samples are a viable alternative to blood samples as a source of DNA for high throughput genotyping [J].
Abraham, Jean E. ;
Maranian, Mel J. ;
Spiteri, Inmaculada ;
Russell, Roslin ;
Ingle, Susan ;
Luccarini, Craig ;
Earl, Helena M. ;
Pharoah, Paul P. D. ;
Dunning, Alison M. ;
Caldas, Carlos .
BMC MEDICAL GENOMICS, 2012, 5
[2]  
Altar C Anthony, 2015, Mol Neuropsychiatry, V1, P145, DOI 10.1159/000430915
[3]   Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges [J].
Arwood, M. J. ;
Chumnumwat, S. ;
Cavallari, L. H. ;
Nutescu, E. A. ;
Duarte, J. D. .
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2016, 9 (05) :233-245
[4]   Development and use of active clinical decision support for preemptive pharmacogenomics [J].
Bell, Gillian C. ;
Crews, Kristine R. ;
Wilkinson, Mark R. ;
Haidar, Cyrine E. ;
Hicks, J. Kevin ;
Baker, Donald K. ;
Kornegay, Nancy M. ;
Yang, Wenjian ;
Cross, Shane J. ;
Howard, Scott C. ;
Freimuth, Robert R. ;
Evans, William E. ;
Broeckel, Ulrich ;
Relling, Mary V. ;
Hoffman, James M. .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2014, 21 (E1) :E93-E99
[5]   A regulatory protocol for pharmacogenomics services [J].
Bristol L.A. .
The Pharmacogenomics Journal, 2002, 2 (2) :83-86
[6]   Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process [J].
Caudle, Kelly E. ;
Klein, Teri E. ;
Hoffman, James M. ;
Mueller, Daniel J. ;
Whirl-Carrillo, Michelle ;
Gong, Li ;
McDonagh, Ellen M. ;
Sangkuhl, Katrin ;
Thorn, Caroline F. ;
Schwab, Matthias ;
Agundez, Jose A. G. ;
Freimuth, Robert R. ;
Huser, Vojtech ;
Lee, Ming Ta Michael ;
Iwuchukwu, Otito F. ;
Crews, Kristine R. ;
Scott, Stuart A. ;
Wadelius, Mia ;
Swen, Jesse J. ;
Tyndale, Rachel F. ;
Stein, C. Michael ;
Roden, Dan ;
Relling, Mary V. ;
Williams, Marc S. ;
Johnson, Samuel G. .
CURRENT DRUG METABOLISM, 2014, 15 (02) :209-217
[7]   Genelex Corporation [J].
Coleman, Howard ;
Ashcraft, Kristine .
PHARMACOGENOMICS, 2008, 9 (04) :469-475
[8]   Information Needs in the Precision Medicine Era: How Genetics Home Reference Can Help [J].
Collins, Heather ;
Calvo, Sherri ;
Greenberg, Kathleen ;
Neall, Lisa Forman ;
Morrison, Stephanie .
INTERACTIVE JOURNAL OF MEDICAL RESEARCH, 2016, 5 (02) :94-99
[9]   Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans [J].
Drozda, Katarzyna ;
Wong, Shan ;
Patel, Shitalben R. ;
Bress, Adam P. ;
Nutescu, Edith A. ;
Kittles, Rick A. ;
Cavallari, Larisa H. .
PHARMACOGENETICS AND GENOMICS, 2015, 25 (02) :73-81
[10]   Implementation of a multidisciplinary pharmacogenomics clinic in a community health system [J].
Dunnenberger, Henry M. ;
Biszewski, Matthew ;
Bell, Gillian C. ;
Sereika, Annette ;
May, Holley ;
Johnson, Samuel G. ;
Hulick, Peter J. ;
Khandekar, Janardan .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (23) :1956-1966